<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8745">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02993107</url>
  </required_header>
  <id_info>
    <org_study_id>ARC004</org_study_id>
    <nct_id>NCT02993107</nct_id>
  </id_info>
  <brief_title>PALISADE Follow-on Study (ARC004)</brief_title>
  <official_title>Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aimmune Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aimmune Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101
      through characterized oral desensitization immunotherapy (CODIT) in peanut-allergic children
      and adults who have completed the ARC003 study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international, multicenter, open-label, 2-arm follow-on study of the safety,
      tolerability, and efficacy of AR101 in peanut-allergic individuals who have completed the
      ARC003 study. This study will explore alternative dosing regimens during extended
      maintenance with AR101.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events including serious adverse events (Safety and Tolerability)</measure>
    <time_frame>38 months</time_frame>
    <description>The frequency of treatment-related adverse events and serious adverse events during the overall study period</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Group 1 (Placebo Crossovers)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects who complete the placebo arm of ARC003 and consent to enroll in ARC004 (Group-1) will cross over to active treatment with AR101 using the same dosing regimen used in ARC003 in open-label fashion. Group 1 subjects may also be assigned to cohorts which test the gradual lengthening of dosing intervals. Following the completion of their longest tested dosing interval, Group 1 subjects will undergo an exit double-blinded placebo-controlled food challenge (DBPCFC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Active Rollovers)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects who successfully complete the active arm of ARC003 and consent to enroll in ARC004 (Group-2) will consecutively enter treatment with AR101 in one of three cohorts which will test alternate dosing intervals. There will be a DBPCFC at the completion of the subject's longest tested dosing interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AR101</intervention_name>
    <description>AR101 powder provided in capsules &amp; sachets</description>
    <arm_group_label>Group 1 (Placebo Crossovers)</arm_group_label>
    <arm_group_label>Group 2 (Active Rollovers)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of the ARC003 study

          -  Written informed consent and/or assent from subjects/guardians as appropriate

          -  Use of effective birth control by sexually active female subjects of child-bearing
             potential

        Exclusion Criteria:

          -  Early discontinuation from the ARC003 study

          -  Meets any longitudinally applicable ARC003 study exclusion criteria

          -  (Group 2 only) Failure to tolerate â‰¥ 443 mg cumulative of peanut protein with no or
             mild symptoms in the ARC003 study Exit DBPCFC

          -  Any other condition that, in the opinion of the Investigator, precludes participation
             for reasons of safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome G. Pinkett, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Director, Clinical Operations</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerome G. Pinkett, MBA</last_name>
    <email>clinicaltrials@aimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Gibson, RN</last_name>
      <phone>501-364-1998</phone>
      <email>gibsoned@archildrens.org</email>
    </contact>
    <investigator>
      <last_name>Stacie Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates of Southern California</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Catlin, LVN</last_name>
      <phone>949-347-8700</phone>
      <phone_ext>1812</phone_ext>
      <email>ccatlin@allergee.com</email>
    </contact>
    <investigator>
      <last_name>Warner Carr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sean N. Parker Center for Allergy Research at Stanford University Packard-El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherri Parulan, NP</last_name>
      <phone>650-564-4568</phone>
      <email>cparulan@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon Chinthrajah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Medical Group and Research Center, APC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Vales, MA</last_name>
      <phone>858-268-2368</phone>
      <phone_ext>115</phone_ext>
      <email>maryvales@allergyandasthma.com</email>
    </contact>
    <investigator>
      <last_name>Michael J. Welch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy &amp; Asthma Centers, P.C.</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Hoffman, RN</last_name>
      <phone>303-632-3646</phone>
      <phone_ext>5</phone_ext>
      <email>kellyh2@coloradoallergy.com</email>
    </contact>
    <investigator>
      <last_name>Leon Greos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Windom Allergy, Asthma and Sinus</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Kastes, RN</last_name>
      <phone>941-927-4888</phone>
      <email>Research@WindomAllergy.com</email>
    </contact>
    <investigator>
      <last_name>Hugh Windom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Allergy &amp; Asthma Clinic, PA</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Maner, LPN</last_name>
      <phone>770-592-4210</phone>
      <email>smaner@atlantaallergy.com</email>
    </contact>
    <investigator>
      <last_name>Stanley Fineman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children, IU Health North Hospital</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Canfield</last_name>
      <phone>317-688-5700</phone>
      <email>accanfie@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Frederick Leickly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital, Div. of Allergy &amp; Immunology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Noh</last_name>
      <phone>617-919-4602</phone>
      <email>Elizabeth.Noe@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Rima Rachid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Asthma &amp; Allergy Center</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Nichols</last_name>
      <phone>402-592-2055</phone>
      <email>anichols@asthmaandallergycenter.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Brooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baker Allergy, Asthma &amp; Dermatology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Castaneda</last_name>
      <phone>503-505-5916</phone>
      <email>jasoncastaneda@aadrc.com</email>
    </contact>
    <investigator>
      <last_name>James Baker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Allergy and Asthma Research, LLC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marla Dangerfield, LPN</last_name>
      <phone>843-576-7485</phone>
      <email>mdangerfield@nationalallergyandasthma.com</email>
    </contact>
    <investigator>
      <last_name>Ned Rupp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Sky Medical Research</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Posey-Sarinana, CRCC</last_name>
      <phone>915-544-2557</phone>
      <email>catposey@westernskymed.com</email>
    </contact>
    <investigator>
      <last_name>Lyndon Mansfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Syring, RN</last_name>
      <phone>210-614-6673</phone>
      <phone_ext>243</phone_ext>
      <email>ssyring@sylvanaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Paul Ratner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Inst. at Virginia Mason; Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Wilder</last_name>
      <phone>206-342-6598</phone>
      <email>katherine.wilder@virginiamason.org</email>
    </contact>
    <investigator>
      <last_name>David Jeong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Allergy &amp; Asthma Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Sadler-Greever, RN</last_name>
      <phone>206-525-5520</phone>
      <phone_ext>1187</phone_ext>
      <email>mgreever@asthmainc.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Tilles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 23, 2017</lastchanged_date>
  <firstreceived_date>December 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AR101</keyword>
  <keyword>Characterized Peanut Allergen</keyword>
  <keyword>CPNA (Characterized Peanut Allergen)</keyword>
  <keyword>OIT (oral immunotherapy)</keyword>
  <keyword>Peanut Allergy</keyword>
  <keyword>Allergy</keyword>
  <keyword>Peanut-Allergic Children</keyword>
  <keyword>Peanut-Allergic Adults</keyword>
  <keyword>Desensitization</keyword>
  <keyword>PALISADE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
